triple agonist glp-1 New strategies for the treatment of obesity and metabolic dysfunctions A review of an investigational

Lifestyle Medicine

Shima Hadidchi, MD, prioritizes providing personalized and up-to-date care for patients seeking weight management and diabetes control

The primary indication for therapy is paramountpatients using these medications for type 2 diabetes management typically require long-term treatment as part of comprehensive disease management, whereas those using GLP-1 agents solely for weight management may have more flexibility depending on their response and circumstances

As obesity and related chronic conditions continue to impact millions of older Americans, this initiative could play a transformative role in improving health outcomes and reshaping how Medicare addresses weight management

These large correlative epidemiological findings support a potential effect of GLP-1 on drug craving